RYTM News and Press, Rhythm Pharmaceuticals Inc. From 11/07/19

Investment thesis: Reduced treatable patient population, lack of placebo and numerous side effects will tank RYTM Diseases with a common genetic origin can be addressed with a single bullet drug or gene-therapy. Rhythm Pharmaceuticals ( RYTM ) is instead applying a “hammer”...

-- Data show treatment effect of setmelanotide on additional secondary endpoints, including body mass index --  -- Additional safety analyses show no significant increases in heart rate or blood pressure -- -- Two oral presentations delivered today during special research for...

Rhythm Pharmaceuticals (NASDAQ: RYTM ): Q3 GAAP EPS of -$1.04 beats by $0.03 . More news on: Rhythm Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

-- Announced Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities -- -- Added Four New MC4R Pathway Obesity Indications to Phase 2 Basket Study and Enrolling Patients -- -- Announced Genetic Sequencing Data Su...

BOSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that it will present clinical data from its two pivotal...

Titan Medical (NASDAQ: TMDI ) -52%  on filing amended prospectus and withdrawing previous milestones. More news on: Titan Medical Inc., Westwater Resources, Inc., TDH Holdings, Inc., Stocks on the move, Read more ...

Gainers:  ABC   +7.0% . CAH   +8.1% . MCK   +7.5% . SNBR   +4.8%.  ENDP   +4.6% . More news on: AmerisourceBergen Corporation, Cardinal Health, Inc., McKesson Corporation, Stocks on the move, , News on ETFs Read more ...

Market Assessment Rhythm Pharmaceuticals ( RYTM ) is a small-cap ($695M) biopharma developing anti-obesity therapeutics for rare and ultra-rare genetic obesity disorders. The lead drug candidate, setmelanotide (formerly RM-493), is a melanocortin-4 receptor (MC4R) agonist peptide in clini...

The following slide deck was published by Rhythm Pharmaceuticals, Inc. in conjunction with this Read more ...

Rhythm Pharmaceuticals (NASDAQ: RYTM ) will announce an update on its R&D programs, genetic sequencing efforts and patient finding initiatives at its R&D event in New York City. More news on: Rhythm Pharmaceuticals, Inc., Healthcare stocks news, Read more ...